Fiche société
Claudio Gobbi
Traitements, essais et publications liés.
Traitements15programmes
Essais13liés
Publications16liées
SourceDBlocale
Traitements
15| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Cladribine Oral TabletProlonged anti CD20 therapy for the treatment of active multiple sclerosis leading to continuous B cell depletion is associated with hypogammaglobulinemia predisposing to a potentially increased risk of serious infections, particularly in the more disabled and aged patients. No data have been published on the sequential use of anti CD20 therapies and cladribine, that is thought to act as an immune reconstitution agent. his study aims at investigating IgG and IgM serum concentration changes at 6 and 12 months after switching to cladribine in patients previously treated with anti CD20 therapies (ie, ocrelizumab ≥1.8 gr or rituximab 3.0 gr) for ≥18 months, as compared to continued anti CD20 therapies. | SEP | À vérifier | Immunomodulation | Switzerland | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | Cancer, Lupus, Myasthénie, SEP | À vérifier | À vérifier | Switzerland | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | Myasthénie | Phase 3 | À vérifier | Italy | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | Lupus | NA | À vérifier | À vérifier | |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | SEP | Phase 3 | À vérifier | Netherlands | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | SEP | Phase 3 | À vérifier | Denmark | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | SEP | Phase 1 | À vérifier | United States | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | SEP | Phase 2 | À vérifier | United States | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | SEP | Phase 2 | À vérifier | United States | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | SEP | Phase 1/2 | À vérifier | United States | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | SEP | À vérifier | Immunomodulation | Greece | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | SEP | Phase 3 | À vérifier | Australia, Belgium, Canada, Denmark, Egypt, France, Hungary, Italy, Netherlands, New Zealand, Norway, Poland, Portugal, Slovakia, Slovenia, South Africa, Sweden, United Kingdom | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | SEP | Phase 2 | À vérifier | United States | À vérifier |
| RituximabThe primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile. | SEP | Phase 2 | À vérifier | United States | À vérifier |
| Cladribine Oral TabletProlonged anti CD20 therapy for the treatment of active multiple sclerosis leading to continuous B cell depletion is associated with hypogammaglobulinemia predisposing to a potentially increased risk of serious infections, particularly in the more disabled and aged patients. No data have been published on the sequential use of anti CD20 therapies and cladribine, that is thought to act as an immune reconstitution agent. his study aims at investigating IgG and IgM serum concentration changes at 6 and 12 months after switching to cladribine in patients previously treated with anti CD20 therapies (ie, ocrelizumab ≥1.8 gr or rituximab 3.0 gr) for ≥18 months, as compared to continued anti CD20 therapies. | SEP | À vérifier | Immunomodulation | Switzerland | À vérifier |
Essais cliniques
13| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Cladribine Oral Tablet | SEP | À vérifier | NCT04640818 | Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy | UNKNOWN |
| Rituximab | SEP | Phase 2 | NCT07731789 | Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma | RECRUITING |
| Rituximab | SEP | Phase 2 | NCT00695409 | Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma | COMPLETED |
| Rituximab | SEP | Phase 3 | NCT00004179 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | COMPLETED |
| Rituximab | SEP | À vérifier | NCT01609023 | CaLLypso — A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia | COMPLETED |
| Rituximab | SEP | Phase 1/2 | NCT00244985 | Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | COMPLETED |
| Rituximab | SEP | Phase 2 | NCT00244855 | Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma | COMPLETED |
| Rituximab | SEP | Phase 2 | NCT00006669 | Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma | WITHDRAWN |
| Rituximab | SEP | Phase 1 | NCT03636503 | Rituximab + Immunotherapy in Follicular Lymphoma | TERMINATED |
| Rituximab | SEP | Phase 3 | NCT04688788 | DanNORMS — Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Rituximab | SEP | Phase 3 | NCT05834855 | Noisy Rebels — Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS | RECRUITING |
| Rituximab | Lupus | NA | NCT00908986 | Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis | WITHDRAWN |
| Rituximab | Myasthénie | Phase 3 | NCT05868837 | Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) | RECRUITING |
Publications
16| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Rituximab | Proteinuria selectivity index as a predictor of remission and rituximab efficacy in primary membranous nephropathy: a single-center retrospective analysis. | Renal failure | ||
| Rituximab | Rituximab remodels the circulating immune landscape in pemphigus vulgaris revealed by high-dimensional immune profiling. | Journal of translational autoimmunity | ||
| Rituximab | Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma. | Oncoimmunology | ||
| Rituximab | [An unusual cause for unilateral eye pain with double vision]. | Praxis | ||
| Rituximab | Immunoglobulin G4-Related Sclerosing Cholangitis: A Review. | Clinics in liver disease | ||
| Rituximab | Use of avacopan in granulomatosis with polyangiitis with predominant gastrointestinal and kidney involvement. | BMJ case reports | ||
| Rituximab | Case Report: Severe ANCA-positive eosinophilic granulomatosis with polyangiitis presenting with Loeffler endocarditis and cryofibrinogenemia-associated digital gangrene successfully treated with rituximab. | Frontiers in immunology | ||
| Rituximab | Post-transplant lymphoproliferative disorder after solid organ transplantation: a comprehensive review. | Frontiers in transplantation | ||
| Rituximab | Severe Immune-Mediated Thrombotic Thrombocytopenic Purpura With High-Titer ADAMTS13 Inhibitors: A Case Report. | Cureus | ||
| Rituximab | Efficacy of Rituximab in Successful Management of Refractory Juvenile Systemic Lupus Erythematosus Complicated with Macrophage Activation Syndrome: A Case Report with Literature Overview. | Indian journal of dermatology | ||
| Rituximab | Fulminant paraneoplastic Ma2 (PNMA2) and zinc finger protein of the cerebellum 4 (ZIC4) antibody-positive encephalitis in triple-negative breast cancer treated with pembrolizumab. | BMJ case reports | ||
| Rituximab | Kidney Survival in Children With Steroid-Resistant Nephrotic Syndrome Treated by Rituximab. | Kidney international reports | ||
| Rituximab | [Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits (PGNMID) Associated with Marginal Zone B-cell Lymphoma: A Case of MGRS in a Patient with Nephrotic Syndrome and Rapidly Progressive Renal Failure]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia | ||
| Rituximab | Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies. | Expert opinion on biological therapy | ||
| Rituximab | Single low-dose daratumumab enhances rituximab efficacy for sustained remission in treatment-refractory autoimmune cytopenias. | Annals of hematology | ||
| Rituximab | Evaluation of the comparative efficacy and safety of obinutuzumab and other follow-up strategies after rituximab failure in refractory nephrotic syndrome. | Pediatric nephrology (Berlin, Germany) |